Robert Driscoll

Work

Analyst Robert Driscoll works at WEDBUSH and is focused on the Healthcare sector with 182 price targets and ratings documented since 2015 spanning on 26 stocks. Analyst's average stock valuation to be materialised ratio is 45.06% with an average time for price targets to be met of 135.73 days.

Most recent stock forecast was given on BCEL, Atreca, Inc at 15-Nov-2022.

Robert Driscoll best performing recommendations are on ABUS (ARBUTUS BIOPHARMA CORPORATION).
The best stock recommendation documented was for ABUS (ARBUTUS BIOPHARMA CORPORATION) at 10/9/2018. The price target of $5 was fulfilled within 1 day with a profit of $1 (16.67%) receiving and performance score of 166.67.

Average potential price target upside

ABUS AKAO ARVN BDTX CDTX CTMX ELEV ETTX FPRX HARP IDRA IDYA IGMS KURA RCUS REPL SURF FHTX ACET BCEL PRTK ZNTL CRVS CMPX CYT DAWN
ABUS AKAO ARVN BDTX CDTX CTMX ELEV ETTX FPRX HARP IDRA IDYA IGMS KURA RCUS REPL SURF FHTX ACET BCEL PRTK ZNTL CRVS CMPX CYT DAWN